Person: YAZİCİ, SERKAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
YAZİCİ
First Name
SERKAN
Name
18 results
Search Results
Now showing 1 - 10 of 18
Publication Predictors of drug survival of biologic therapies in psoriasis patients (vol 45, pg 813, 2020)(Taylor & Francis, 2020-08-31) Zorlu, Özge; Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Yazıcı, Serkan; YAZİCİ, SERKAN; Sığırlı, Deniz; SIĞIRLI, DENİZ; Budak, Ferah; BUDAK, FERAH; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; Aydoğan, Kenan; AYDOĞAN, KENAN; Cevhertas, Laçin; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim; 0000-0001-5555-130X; 0000-0001-6407-0962; 0000-0001-7625-9148; 0000-0002-0193-1128; 0000-0003-2287-3569; AAH-1388-2021; AAH-6216-2021; AAA-7472-2021; F-4657-2014; IZP-9398-2023; AAH-2459-2021Publication Retrospective analysis of the forty-six patients with bullous pemphigoid followed-up in our clinic(Deri Zuhrevi Hastaliklar Dernegi, 2016-01-01) Yazıcı, Serkan; BÜLBÜL BAŞKAN, EMEL; YAZİCİ, SERKAN; Başkan, Emel Bülbül; Tunalı, Şükran; Aydoğan, Kenan; AYDOĞAN, KENAN; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıkları Anabilim Dalı.; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-1388-2021; AAH-6216-2021; AAH-2459-2021Background and Design: Bullous pemphigoid (BP) is an autoimmune disease characterised by widespread itchy plaques and subepithelial blisterings and usually affects the elderly population. Due to the chronic nature of the disease, to prevent the side effects of chronic steroid treatment, adjuvant immunosuppressive (mycophenolate mofetil, azathioprine, methotrexate) and anti-inflammatory (tetracycline, nicotinamide, dapsone) agents may be used. In this study, we retrospectively evaluated the clinical and demographic characteristics and applied treatments of 46 patients with the diagnosis of BP and compared with literature data.Materials and Methods: We retrospectively evaluated the records of 46 patients who received clinical and histopathological diagnosis of BP and followed up in our clinic between 2006 and 2013.Results: Of the 46 patients, 22 were female and 24 male. The mean age of onset was 69.54 years (range: 18-105). The duration of the lesion ranged from 1 week to 10 months with a median duration of 8 weeks. The most frequent comorbid chronic disease was hypertension detected in 28 (60.8%) patients. Only four patients had a history of malignancy before the onset of the disease. Nineteen patients (42%) used more than 5 agents for comorbid diseases. Thirty-two patients (69.5%) used systemic corticosteroids alone and ten (22%) patients needed additional adjuvant therapies.Conclusion: BP is a major cause of morbidity in the elderly population receiving multiple drug treatment. To avoid the side effects of steroid therapy, especially in patients with severe disease, short-term use of additional immunosuppressive agents appears to be safe and effective.Publication Clinical and demographical characteristics of familial Behcet's disease (southeast Marmara region)(Karger, 2019-01-01) Kalın, Zübeyde Ceylan; Sarıcaoğlu, Hayriye; Yazıcı, Serkan; Aydoğan, Kenan; Başkan, Emel Bülbül; SARICAOĞLU, HAYRİYE; YAZİCİ, SERKAN; AYDOĞAN, KENAN; BÜLBÜL BAŞKAN, EMEL; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı.; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-2459-2021; AAH-6216-2021; AAH-1388-2021; DQE-8993-2022Background: Familial aggregation in Behcet's disease (BD) has been reported in Turkish and Japanese populations. While the frequency of familial cases has been reported to be 2-5% worldwide, this rate reaches up to 15% in the Middle East. Objective: This study aimed to determine the incidence of familial BD cases followed in the BD polyclinic and to compare their clinical and demographic characteristics to those observed in sporadic cases. Methods: Data related to BD patients who were followed between 1995 and 2014 were collected from computerized archive records and were assessed for detailed family histories. Only first-degree relatives (brother, sister, mother, father, children) were considered to be cases of familial BD. Clinical and demographic features were retrieved. Our BD polyclinic is located in the Southeast Marmara Region in Turkey. Results: BD was detected in 36 first-degree relatives of 33 patients out of 840 patients with BD. A total of 45 patients were diagnosed as familial BD; 23 were female, and 22 were male. In our patients, the incidence of familial BD was determined to be 3.9%. The rates for HLA-B5 positivity, ocular involvement, genital ulcers, and erythema nodosum were determined to be 86.6% (26/30), 26.6%, 82.2%, and 60%, respectively. None of the patients had neurological involvement, but 2 had vascular involvement. Conclusion: This study may contribute to the epidemiological data of BD from Turkey. (C) 2019 S. Karger AG, BaselPublication Rates of skincare product and cosmetic procedure use in patients with acne vulgaris and the effective factors: A multicenter study with 1,755 patients(Wiley, 2022-06) Kayıran, Melek Aslan; Karadağ, Ayşe Serap; Alyamaç, Gökçen; Cemil, Bengü Çevirgen; Demirseren, Duriye Deniz; Demircan, Yuhanize Tas; Aksoy, Hasan; Kilic, Sevilay; Polat, Asude Kara; Yuksel, Esma Inan; Kalkan, Goknur; Aksac, Sema Elibuyuk; Kutlu, Omer; Kaksi, Sumeyye Altintas; Akturk, Aysun Sikar; Akbulut, Tugba Ozkok; Solak, Sezgi Sarikaya; Topal, Ilteris Oguz; Yazici, Serkan; Ozden, Hatice Kaya; Koska, Mahmut Can; Uzuncakmak, Tugba Kevser; Ataseven, Arzu; Işık, Begüm; Alpsoy, Erkan; YAZİCİ, SERKAN; Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı; 0000-0001-6407-0962; AAH-2459-2021Background: Skincare products and cosmetic procedures are used as an adjunct or complementary to conventional drug therapy for acne vulgaris (AV). Objective: To evaluate the use of skincare products and the frequency of cosmetic procedures in AV treatment. Methods: A total of 1,755 patients with AV completed the survey prepared by the researchers and the Cardiff Acne Disability Index (CADI) questionnaire. The clinical findings and the Food and Drug Administration (FDA) severity scores were recorded by the dermatologists. Results: For AV, 66.7% of the patients stated that they used skincare products and 26.7% had undergone cosmetic procedures. The use of skincare products was statistically significantly higher in women (female: 74.5%, male: 57.7%, p < 0.0001); older people (users: 22 ± 7.6years, non-users: 21.2 ± 5.7 years, p < 0.0001); patients with a higher CADI score (users: 7 ± 3.7, non-users: 6.9 ± 4.3, p = 0.010); FDA severity score 2 and 3 (FDA-1: 58.1%; FDA-2: 72.4%, FDA-3: 73%, FDA-4: 67%, p < 0.0001); long-term disease (users: 57 ± 43 months; non-users: 47.7 ± 42.3 months, p < 0.0001); facial involvement (present: 70.2%, absent: 51.4%, p = 0.017); high income levels (users: 73.5%; non-users: 26.5%, p = 0.001); and graduate or post-graduate degrees (undergraduate≤%62.8, graduate≥%76.8, p < 0.0001). The rate of cosmetic procedures was higher in those with higher CADI scores (users: 7.8 ± 3.8; non-users: 7.1 ± 3.96, p < 0.0001); older patients (users: 22.7 ± 10.7 years; non-users: 21.3 ± 5 years, p < 0.0001); high school (25.6%); and graduate (28.9%) education (p = 0.043), those with lower disease severity (FDA-1: 31.1%; FDA-2: 28.5%, FDA-3: 27.1%, FDA-4: 20.4%, p = 0.022); smokers (smokers: 32.5%; non-smokers: 25.5%, p = 0.020), and those with AV in the family (present: 29.8%; absent: 24.2%, p = 0.009). The patients most frequently used cleansers (85.2%) as cosmetic products, and most commonly underwent skincare treatment (71%) as an interventional procedure. They mostly learned about such products and methods from the Internet, and 33.3% of the participants had undergone procedures performed by non-physicians. Conclusion: The patients generally choose skincare products as a result of their Internet search and sometimes have these procedures performed by non-physicians. Dermatologists should be aware of this situation and inform their patients about appropriate products and procedures.Publication Social media use in patients with acne vulgaris: What do patients expect from social media?(Wiley, 2021-06-01) Kayıran, Melek Aslan; Karadağ, Ayşe Serap; Alyamaç, Gökçen; Cemil, Bengü Çevirgen; Demirseren, Düriye Deniz; Aksoy, Hasan; Kılıç, Sevilay Oğuz; Demircan, Yuhanize Taş; Yüksel, Esma İnan; Kalkan, Göknur; Yaşar, Gülbin; Aktürk, Aysun Sıkar; Kutlu, Ömer; Kaksi, Sümeyye Altıntaş; Aksaç, Sema Elibüyük; Erdoğan, Hilal Kaya; Özden, Hatice Kaya; Solak, Sezgi Sarıkaya; Koska, Mahmut Can; Yazıcı, Serkan; YAZİCİ, SERKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı.; AAH-2459-2021Background Acne vulgaris (AV) may affect external appearance and significantly deteriorate the quality of life of patients. Therefore, patients make various inquiries about their disease and seek treatment options.Aims To investigate the social media usage habits of patients with AV concerning their diseases, and their recommendations for dermatologists related to social media use.Methods A total of 1609 patients with AV completed the survey prepared by the authors and the Cardiff Acne Disability Index questionnaire. The Food and Drug Administration severity scores and clinical information of the patients were noted by their physicians.Results Of the 1,489 patients who stated that they used social media, 46.31% regularly and 28.77% sometimes referred to these sources to make inquiries about AV. Social media usage for AV was statistically significantly higher in women, participants with short term and severe disease, those with a moderate income level, and those using topical treatment and cosmetics. They mostly used Google (67%), Instagram (54%), and YouTube (49%). While 76% of the participants stated that they did not share what they saw on the Internet with their doctor. Of the respondents, 18.5% were trying to contact their dermatologists through the Internet, and 69.73% would prefer experts such as dermatologists to post-AV-related content.Conclusions Our study shows that patients frequently resort to social media to seek information about AV. In the changing digital world order, it is observed that there is a need for dermatologists to use social media more actively to share accurate information about AV.Publication The ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans(Assoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo, 2021-01-01) Tanriverdi, Ozgur; Ozsen, Mine; ÖZŞEN, MİNE; Deligonul, Adem; DELİGÖNÜL, ADEM; Yazici, Serkan; YAZİCİ, SERKAN; Cetintas, Sibel Kahraman; Yalcinkaya, Ulviye; YALÇINKAYA, ÜLVİYE; Sahin, Ahmet Bilgehan; ŞAHİN, AHMET BİLGEHAN; Orhan, Sibel Oyucu; OYUCU ORHAN, SİBEL; Ocak, Birol; OCAK, BİROL; Evrensel, Turkkan; EVRENSEL, TÜRKKAN; Kahveci, Ramazan; KAHVECİ, RAMAZAN; Cubukcu, Erdem; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Plastik Cerrahi ve Estetik Anabilim Dalı.; 0000-0001-6407-0962; 0000-0002-5771-7649; 0000-0002-7846-0870; 0000-0002-0598-7284; 0000-0001-7537-1699; AAJ-8314-2021; AEC-2238-2022; AAM-4927-2020; M-2172-2015Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue sarcoma that originates from the dermis or subcutaneous tissue in the skin. While its prognosis is generally favorable, disease recurrence is relatively frequent. Since morbidity after repeated surgery may be significant, an optimized prediction of recurrence-free survival (RFS) has the potential to improve current management strategies. The purpose of this study was to investigate the prognostic value of the Ki-67 proliferation index with respect to RFS in patients with DFSP We retrospectively analyzed data from 45 patients with DFSP. We calculated the Ki-67 proliferation index as the percentage of immunostained nuclei among the total number of tumor cell nuclei regardless of the intensity of immunostaining. We constructed univariate and multivariate Cox proportional hazards regression models to identify predictors of RFS. Among the 45 patients included in the study, 8 developed local recurrences and 2 had lung metastases (median follow-up: 95.o months; range: 5.2-412.4 months). The RFS rates at 60, 120, and 240 months of follow-up were 83.8%, 76.2%, and 65.3%, respectively. The median Ki-67 proliferation index was 14%. Notably, we identified the Ki-67 proliferation index as the only independent predictor for RFS in multivariate Cox proportional hazards regression analysis (hazard ratio = 1.106, 95% confidence interval = 1.019-1.200, p = 0.016). In summary, our results highlight the potential usefulness of the Ki-67 proliferation index for facilitating the identification of patients with DFSP at a higher risk of developing disease recurrences.Publication Is there any association between mycosis fungoides and Th-1,Th-2 cytokines and transforming growth factor-beta 1 gene polymorphisms?(Deri Zuhrevi Hastaliklar Dernegi, 2018-01-01) Yazıcı, Serkan; YAZİCİ, SERKAN; Aydoğan, Kenan; AYDOĞAN, KENAN; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; BÜLBÜL BAŞKAN, EMEL; Tunalı, Şükran; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-2459-2021; AAH-1388-2021; AAH-6216-2021Background and Design: Cytokines are considered to play a crucial role in the development of mycosis fungoides (MF). Cytokine production is under genetic control and allelic variations of cytokine genes are associated with lower or higher production of cytokines. The aim of this study was to determine any possible cytokine gene polymorphisms that may be a risk factor for the development or progression of MF.Materials and Methods: Genotyping of interferon-gamma (IFN-gamma)+874, interleukin (IL)-10-1082, IL-6-174, transforming growth factor-beta 1 (TGF-beta 1), codon 10 and codon 25, and tumor necrosis factor-alpha (TNF-alpha)-308 was undertaken in 55 Turkish patients with MF and compared to 50 healthy controls. Polymerase chain reaction (PCR)-restriction fragment length polymorphism was applied for IFN-gamma+874, IL-10-1082, IL6-174 and TNF-alpha-308 gene polymorphisms. TGF-beta 1 was genotyped by direct DNA sequencing of PCR amplified gene products for codon 10 and codon 25 polymorphisms.Results: Genotype distributions showed no significant difference between the patients and the controls for any of the five investigated cytokines. There was no significant difference between advanced stage and early stage cases and healthy controls.Conclusion: None of the studied cytokine gene polymorphisms are risk factors for the development or progression of MF in the Turkish population, however, further studies are needed.Publication A report of 13 cases of merkel cell carcinoma: Single-center experience and review of the literature(Korean Dermatological Assoc, 2019-06-01) Yazıcı, Serkan; Yazıcı, Elif Irmak; Adım, Şaduman Balaban; Başkan, Emel Bülbül; Aydoğan, Kenan; Sarıcaoğlu, Hayriye; YAZİCİ, SERKAN; Yazıcı, Elif Irmak; BALABAN ADIM, ŞADUMAN; BÜLBÜL BAŞKAN, EMEL; AYDOĞAN, KENAN; SARICAOĞLU, HAYRİYE; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-1388-2021; AAH-2459-2021; AAH-6216-2021; IHQ-3086-2023; EMN-0789-2022; DPU-8534-2022Background: There is limited data knowledge of Merkel cell carcinoma (MCC) in Turkey aside from a few case reports. Objective: The aim of this study was to describe the clinical characteristics, demographic features, therapeutic parameters, and outcome of primary cutaneous MCC cases from Turkey. Methods: Digital medical records of the 13 MCC patients who were followed-up at a tertiary referral center were retrospectively analyzed. Clinic, demographic, tumor characteristics, and survival of the patients were retrieved. Results: Most of our patients were elderly. Female predominance was noticed. The most common primary site of the tumors was the lower extremities. The overall survival was 42 months, 68% at first year, 68% at third years, and 29% at fifth years. Conclusion: This is the first largest report from Turkish population with female predominance, and lower extremity tendency.Publication Factors related to omalizumab drug survival and treatment responses in chronic urticaria(Karger, 2022-08-29) Hasal, Eda; SARICAOĞLU, HAYRİYE; Bülbül Başkan, Emel; BÜLBÜL BAŞKAN, EMEL; YAZİCİ, SERKAN; Yazıcı, Serkan; Aydoğan, Kenan; AYDOĞAN, KENAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; 0000-0001-6310-5107; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-6216-2021Introduction: This study aimed to evaluate factors affecting drug survival and treatment response in patients with chronic urticaria treated with omalizumab in clinical practice. Methods: This study included 386 patients with chronic urticaria. Demographic characteristics, clinical features, laboratory parameters, and omalizumab treatment data were analyzed retrospectively. The 7-day urticaria activity score (UAS7) and urticaria control test (UCT) were used to assess disease severity and treatment responses. Results: Well-controlled disease (UAS7 <= 6) was achieved in 59.3% of patients at a median of 2 months. Complete response was significantly higher in patients treated with omalizumab for >= 12 months (p < 0.001). Family history of asthma (p = 0.01) was less frequent, and disease duration (p = 0.041) was shorter in patients with well-controlled disease. Total treatment duration was longer in patients with relapse (p < 0.001) and serum Helicobacter pylori IgA positivity (p = 0.029). Discussion/Conclusion: Treatment response is better in patients treated with omalizumab for >= 12 months. However, prolonged treatment does not prevent relapse. Our findings suggest that continuous or intermittent therapy is an appropriate alternative treatment option in patients with severe chronic urticaria; however, continuous therapy can be preferred to maintain the patient's quality of life.Publication Keloid formation following ear piercing through the transitional zone(Elsevier Science Inc, 2023-06-30) Zorlu, Özge; Yazıcı, Serkan; Adım, Şaduman Balaban; Zorlu, Özge; YAZİCİ, SERKAN; BALABAN ADIM, ŞADUMAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0001-5555-130X; 0000-0001-6407-0962; IAL-9735-2023; EHG-3420-2022; EMN-0789-2022